Phase 2Recruiting
Trial of Trastuzumab Deruxtecan in Previously Treated HER2
Sponsored by Yale University
About this study
The purpose of this study is to test the good and bad effects of a drug called trastuzumab deruxtecan (T-DXd) in adult patients with metastatic HER2-negative breast cancer and which patients might benefit the most from T-DXd.
Enrolling at this location
University of Rochester Medical Center
Rochester, New York
I'm interestedThis study also enrolls at 2 other locations. See all.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.